Over 450,000 new cases of pancreatic cancer were diagnosed in 2018, with 430,000 deaths.1 Overall five-year survival rates for the disease in the U.S. are 9%.2
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries doi.org/10.3322/caac.21492
- American Cancer Society. Cancer Facts & Figures 2019. Atlanta:American Cancer Society; 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
Phase II study
REACtiVe (Rotterdam pancrEAtic Cancer Vaccination trial) is an open label phase II study in adult patients with surgically resected pancreatic cancer who have received adjuvant standard of care treatment.
The primary objective of this phase II study is to investigate feasibility of an allogeneic tumour cell lysate (PheraLys) loaded onto autologous dendritic cells (MesoPher) in resected pancreatic cancer patients who received adjuvant standard of care treatment. The secondary objective of the study is to investigate safety and toxicity as well as immune-response of MesoPher in these patients.